Gilead is committing $50m to a drug discovery partnership with Tony Johnson , which has developed the Kidney Goldfinch Bio of genetics and clinical data regarding the kidney. Johnson notes a mid-stage program for an ASK1 drug in fibrosis, where the company has been centered on a variety of therapies. Gilead has provided $50m in upfront cash, along with $50m for equity and $ 54 m to support research into diabetic kidney disease. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.
Gilead is committing $50m to a drug discovery partnership with Tony Johnson , which has developed the Kidney Goldfinch Bio of genetics and clinical data regarding the kidney. Gilead has provided $50m in upfront cash, along with $50m for equity and $ 54 m to support research into diabetic kidney disease. Goldfinch CEO Tony Johnson said the start-up will consider launching an IPO once it is closer to proof of concept data for new drugs.